LY-2584702 free base

CAS No. 1082949-67-4

LY-2584702 free base( —— )

Catalog No. M23290 CAS No. 1082949-67-4

LY2584702 is a selective, ATP-competitive p70S6K inhibitor(IC50: 4 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 49 In Stock
5MG 104 In Stock
10MG 135 In Stock
25MG 299 In Stock
50MG 403 In Stock
100MG 592 In Stock
500MG 1242 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    LY-2584702 free base
  • Note
    Research use only, not for human use.
  • Brief Description
    LY2584702 is a selective, ATP-competitive p70S6K inhibitor(IC50: 4 nM).
  • Description
    LY2584702 is a selective, ATP-competitive p70S6K inhibitor(IC50: 4 nM).
  • In Vitro
    LY-2584702 (LY2584702) inhibits phosphorylation of the S6 ribosomal protein (pS6) in HCT116 colon cancer cells with an IC50 of 0.1-0.24 μM. For pS6 inhibition in cells, the IC50=100 nM. LY-2584702 has some activity against the S6K-related kinases MSK2 and RSK at high concentrations (enzyme assay IC50=58-176 nM). LY-2584702 inhibits S6K activity in EOMA cells, as determined by the phosphorylation of its downstream effector S6, in a dose-dependent manner. Proliferation of A549 is significantly inhibited by LY-2584702 (LY2584702) treating over 24 h at 0.1 μM (P<0.05); and the trend of decline is more conspicuous with longer treatment and/or with the increased drug concentration (all P<0.05). Similar results are also observed in SK-MES-1, although the obvious inhibition is led by LY-2584702 at 0.6 μM (P<0.05), much higher than that of A549.
  • In Vivo
    LY-2584702 demonstrates significant single-agent efficacy in both U87MG glioblastoma and HCT116 colon carcinoma xenograft models at two dose levels of 2.5 mg/kg twice daily (BID) and 12.5 mg/kg BID. LY-2584702 demonstrates statistically significant tumour growth reduction at TMED50 (threshold minimum effective dose 50%) (2.3 mg/kg) and TMED90 (10 mg/kg) in the HCT116 colon carcinoma xenograft model. To examine the role of S6K in vivo, EOMA cells expressing shAkt3 are implanted in nu/nu mice, then treated for 14 days with LY-2584702 or Rapamycin. Analysis of tumors removed after 14 days shows that LY-2584702 inhibits S6 phosphorylation almost as effectively as Rapamycin. Loss of Akt3 increases tumor growth as compared with pLKO. LY-2584702 treatment alone does not significantly affect the growth of pLKO tumors. However, LY-2584702 significantly reduces the growth of tumors with shAkt3.
  • Synonyms
    ——
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    mTOR
  • Recptor
    mTOR (p70S6K)
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1082949-67-4
  • Formula Weight
    445.42
  • Molecular Formula
    C21H19F4N7
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:10 mM,warmed with 50oC water bath
  • SMILES
    CN1C=C(N=C1C2CCN(CC2)C3=NC=NC4=C3C=NN4)C5=CC(=C(C=C5)F)C(F)(F)F
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Hollebecque A, Houédé N, Cohen EE, Massard C, Italiano A, Westwood P, Bumgardner W, Miller J, Brail LH, Benhadji KA, Soria JC. A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours. Eur J Cancer. 2014 Mar;50(5):876-84. doi: 10.1016/j.ejca.2013.12.006. Epub 2014 Jan 20.
molnova catalog
related products
  • BIA

    BIA is an inhibitor of the interaction between TMBIM6 and mTORC2, which ultimately blocks AKT activation and cancer progression.

  • GPI-1046

    GPI-1046 is a non-immunosuppressive ligand of the immunophilin FKBP12.

  • Torin2

    Torin2 is a potent, selective, orally available inhibitor of mTOR, inhibits mTORC1-dependent T389 phosphorylation on S6K with IC50 of 0.25 nM.